These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30785951)

  • 1. Correction: Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA.
    Li Y; Appius A; Pattipaka T; Feyereislova A; Cassidy A; Ganti AK
    PLoS One; 2019; 14(2):e0212831. PubMed ID: 30785951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study.
    Ramlau R; Cufer T; Berzinec P; Dziadziuszko R; Olszewski W; Popper H; Bajcic P; Dusšk L; Zbozinkova Z; Pirker R;
    J Thorac Oncol; 2015 Sep; 10(9):1370-1374. PubMed ID: 26291014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients.
    Batra U; Lokeshwar N; Gupta S; Shirsath P
    Indian J Cancer; 2017 Dec; 54(Supplement):S37-S44. PubMed ID: 29292707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Clinical Significance of the Insulin-Like Growth Factor-1 Receptor Polymorphism in Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation.
    Liu TC; Hsieh MJ; Liu MC; Chiang WL; Tsao TC; Yang SF
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor T790M mutation: A major culprit in the progression of epidermal growth factor receptor-driven non-small cell lung cancer and the role of repeat biopsy.
    Aggarwal S; Patil S; Rohtagi N
    Indian J Cancer; 2017 Dec; 54(Supplement):S15-S24. PubMed ID: 29292704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas
    Satouchi M; Tanaka H; Yoshioka H; Shimokawaji T; Mizuno K; Takeda K; Yoshino I; Seto T; Kurata T; Tashiro N; Hagiwara K
    Lung Cancer; 2017 Sep; 111():190-194. PubMed ID: 28838392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction: DeltaNp63alpha-Mediated Induction of Epidermal Growth Factor Receptor Promotes Pancreatic Cancer Cell Growth and Chemoresistance.
    Danilov AV; Neupane D; Nagaraja AS; Feofanova EV; Humphries LA; DiRenzo J; Korc M
    PLoS One; 2018; 13(2):e0192927. PubMed ID: 29420628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer.
    Sun JM; Rampal S; Lee G; Lee J; Choi YL; Parasuraman B; Guallar E; Cho J; Shim YM
    Lung Cancer; 2013 May; 80(2):191-6. PubMed ID: 23384673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction: Epidermal Growth Factor Receptor in Prostate Cancer Derived Exosomes.
    Kharmate G; Hosseini-Beheshti E; Caradec J; Chin MY; Tomlinson Guns ES
    PLoS One; 2016; 11(6):e0157392. PubMed ID: 27295211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer.
    Stone E; Allen HA; Saghaie T; Abbott A; Daniel R; Mead RS; Kohonen-Corish M; Plit M; Morgan L
    Intern Med J; 2014 Dec; 44(12a):1188-92. PubMed ID: 25228365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
    Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
    [No Abstract]   [Full Text] [Related]  

  • 16. Epidermal growth factor receptor mutations in 510 Finnish non--small-cell lung cancer patients.
    Mäki-Nevala S; Rönty M; Morel M; Gomez M; Dawson Z; Sarhadi VK; Telaranta-Keerie A; Knuuttila A; Knuutila S
    J Thorac Oncol; 2014 Jun; 9(6):886-91. PubMed ID: 24828666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction: Retraction: A Functional Nuclear Epidermal Growth Factor Receptor, Src and Stat3 Heteromeric Complex in Pancreatic Cancer Cells.
    PLOS ONE Staff
    PLoS One; 2019; 14(4):e0216490. PubMed ID: 31039211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors.
    Choi YJ; Park GM; Rho JK; Kim SY; So GS; Kim HR; Choi CM; Lee JC
    PLoS One; 2019; 14(3):e0213984. PubMed ID: 30870512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction: Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis.
    Schad F; Thronicke A; Steele ML; Merkle A; Matthes B; Grah C; Matthes H
    PLoS One; 2022; 17(8):e0273387. PubMed ID: 35972953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.